What is the MannKind Corporation stock price forecast?

MannKind Corporation is currently trading at $3.66. View real-time AI analysis on Alpha Lenz.

What is MannKind Corporation insider trading activity?

View the latest insider trading data for MannKind Corporation on Alpha Lenz.

What is MannKind Corporation's P/E ratio?

MannKind Corporation's P/E ratio is 190.8.

MannKind Corporation

NASDAQ · MNKD

$3.66-0.09(-2.40%)Pre-market

Ask about MannKind Corporation's future dividend policy...

Alpha Chat Insight

“MannKind Corporation trades at a P/E of 190.8 (premium valuation) with modest ROE of -9.0%. 3Y revenue CAGR of 51.8% highlights clear growth momentum.”

Ask for details →

Company Overview

MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutic products for patients with serious medical conditions. Its primary product is Afrezza, a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes mellitus. This novel approach provides an alternative to traditional insulin delivery methods, offering convenience and potentially improved patient compliance. MannKind Corporation operates in the health care sector, specifically targeting the pharmaceuticals and biotechnology industries. The company is dedicated to addressing unmet medical needs through its proprietary Technosphere formulation technology, which facilitates the pulmonary delivery of therapeutic molecules. Beyond diabetes management, MannKind seeks to explore additional clinical applications for its technology in areas like oncology and endocrinology. Founded in 1991 and headquartered in Westlake Village, California, MannKind has a significant presence in the medical and biotech markets. Its commitment to innovation and patient-centered solutions highlights its role in shaping future therapeutics, contributing to advancements in both diabetes care and potential new frontiers for drug delivery systems.

CEODr. Michael E. Castagna Pharm.D.

Websitehttps://www.mannkindcorp.com

SectorHealthcare

IndustryBiotechnology

Employees403

Company Statistics

FY 2025

Profile

$1.12BMarket Cap

$348.97MRevenue

0.00Shares Out

403Employees

Margins

74.79%Gross

18.82%EBITDA

13.34%Operating

0.40%Pre-Tax

1.68%Net

Valuation

190.80P/E

-21.92P/B

3.21EV/Sales

21.49EV/EBITDA

81.72P/FCF

Growth (CAGR)

51.80%Rev 3Yr

39.89%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

0.99%ROA

-9.03%ROE

6.62%ROIC

Financial Health

$74.88MCash & Cash Equivalents

$768.32MNet Debt

-1652.63%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“MannKind Corporation trades at a P/E of 190.8 (premium valuation) with modest ROE of -9.0%. 3Y revenue CAGR of 51.8% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

MannKind Corporation (ticker: MNKD) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 403 employees. Market cap is $1.1B.

The current price is $3.66 with a P/E ratio of 190.8x and P/B of -21.92x.

ROE is -9.03% and operating margin is 13.34%. Annual revenue is $349M.